397
Participants
Start Date
February 18, 2019
Primary Completion Date
March 30, 2021
Study Completion Date
March 30, 2021
BX-1
BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
Placebo
Placebo of BX-1, oral solution
Investigative Site, Budapest
Investigative Site, Budapest
Investigative Site, Budapest
Investigative Site, Tatabánya
Investigative Site, Miskolc
Investigative Site, Debrecen
Investigative Site, Szolnok
Investigative Site, Szeged
Investigative Site, Győr
Investigative Site, Prague
Investigative Site, Prague
Investigative Site, Prague
Investigative Site, Salt
Investigative Site, Prague
Investigative Site, Madrid
Investigative Site, Málaga
Investigative Site, Pilsen
Investigative Site, Teplice
Investigative Site, Valencia
Investigative Site, Hradec Králové
Investigative site, Hradec Králové
Investigative Site, Choceň
Investigative Site, Havířov
Investigative Site, Olomouc
Investigative Site, Freiburg im Breisgau
Investigative Site, Ulm
Investigative Site, Bydgoszcz
Investigative Site, Częstochowa
Investigative Site, Katowice
Investigative Site, Katowice
Investigative Site, Katowice
Investigative Site, Katowice
Investigative Site, Krakow
Investigative Site, Plewiska
Investigative Site, Poznan
Investigative Site, Warsaw
Investigative Site, Warsaw
Investigative Site, Barcelona
Investigative Site, Barcelona
Investigative Site, L'Hospitalet de Llobregat
Lead Sponsor
Bionorica SE
INDUSTRY